STORM Therapeutics
Cambridge, United States · Biotechnology, Health Care, Therapeutics
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platfor
Key facts
- Headquarters
- Cambridge, United States
- Employees
- 32
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- stormtherapeutics.com
- Company page
Recent activity at STORM Therapeutics
STORM Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2026 | Series C | $56.0M |
| Dec 2022 | Series B | $30.0M |
Leadership
- Michael Johnston, Senior Director of Finance
- Sapna Mistry, Executive Director, Program Team Lead
- Beth Thomas, Vice President Medicinal Chemistry
- Marguerite Hutchinson, Chief Business Officer
- Eric Martin, Chief Development Officer
- Marguerite Hutchinson, Chief Business Officer
- Oliver Rausch, Chief Scientific Officer
Verified email and direct lines for STORM Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
STORM Therapeutics in the news
Companies similar to STORM Therapeutics
- AIM ImmunoTech · Biotechnology, Health Care, Therapeutics
- ProteinQure · Biotechnology, Health Care, Therapeutics
- Qualigen Therapeutics · Biotechnology, Health Care, Therapeutics
- Noema Pharma · Biotechnology, Health Care, Therapeutics
- Gain Therapeutics · Biotechnology, Health Care, Therapeutics
About STORM Therapeutics: questions and answers
What does STORM Therapeutics do?
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platfor
Where is STORM Therapeutics headquartered?
STORM Therapeutics is headquartered in Cambridge, United States.
How many employees does STORM Therapeutics have?
STORM Therapeutics has about 32 employees.
Has STORM Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for STORM Therapeutics. The most recent, Series C of $56.0M, was in Apr 2026.
Who leads STORM Therapeutics?
Beth Thomas is a Vice President Medicinal Chemistry at STORM Therapeutics.
What is the latest news on STORM Therapeutics?
On Apr 16, 2026, STORM Therapeutics Raises $56M in Series C Funding. The funds will support the advancement of STC-15, a first-in-class cancer therapy.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy